Adipose Derived Stem Cell Therapy Market includes Production and Market Share by Type (2020-2026) – Cole of Duty

The globalAdipose Derived Stem Cell Therapy Marketreport by wide-ranging study of the Adipose Derived Stem Cell Therapy industry which covers comprehensively all aspects of the different industry verticals. This includes its past performance analysis, latest market performance estimation for the current year based on the drivers, challenges and trend. Furthermore, the future projection for the forecast period is also covered within the global Adipose Derived Stem Cell Therapy industry report. The Adipose Derived Stem Cell Therapy market segmentation provides the customer a comprehensive overview of the overall Adipose Derived Stem Cell Therapy industry, assisting them in making informed decisions through key insights into the Adipose Derived Stem Cell Therapy market. The segmentation is done on the basis of product, region, and application.

Major Players: Customized Adipose Derived Stem Cell Therapy Market: BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

The report provides both quantitative and qualitative information of global Adipose Derived Stem Cell Therapy market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Adipose Derived Stem Cell Therapy is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Adipose Derived Stem Cell Therapy market was valued at USD _ million/billion.

We do offer a sample of this report. Kindly go through the following information in order to access sample copy.

This report sample includes

Brief Introduction to the research report. Table of Contents (Scope covered as a part of the study) Top players in the market Research framework (presentation) Research methodology adopted by Coherent Market Insights

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2357

Market by Region:

North America (U.S., Canada, Mexico) Europe (Germany, U.K., France, Italy, Russia, Spain etc.) Asia-Pacific (China, India, Japan, Southeast Asia etc.) South America (Brazil, Argentina etc.) The Middle East and Africa (Saudi Arabia, South Africa etc.)

Key Content of Chapters as follows (Including and can be customized) :

Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Global Market by company, Type, Application & Geography Part 3-4: Asia-Pacific Market by company, Type, Application & Geography Part 5-6: Europe Market by company, Type, Application & Geography Part 7-8: North America Market by company, Type, Application & Geography Part 9-10: South America Market by company, Type, Application & Geography Part 11-12: Middle East & Africa Market by company, Type, Application & Geography Part 13: Company information, Sales, Cost, Margin etc. Part 14: Conclusion

Some Important Highlights From The Report Include:

Request Discount option enables you to get discounts on the actual price of the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss your allocated budget and would provide discounts.

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2357

Competitive Landscape

The analysts have provided a comprehensive analysis of the competitive landscape of the global Adipose Derived Stem Cell Therapy market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [emailprotected]

Read the original here:
Adipose Derived Stem Cell Therapy Market includes Production and Market Share by Type (2020-2026) - Cole of Duty

Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder – Newswise

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

Continue reading here:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-…

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Canine Arthritis Treatment Market is expected to exceed more than US$ 3.18 Billion by 2024 at a CAGR of 4.4% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/canine-arthritis-treatment-market

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

The Canine Arthritis Treatment Market is segmented on the lines of its treatment type, route of administration, end users and regional. Basis of End-User is segmented into Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores and E-commerce. Based on Treatment Type it covers Non-steroidal anti-inflammatory drugs, Opioids and Stem Cell Therapy. Based on route of administration it covers Oral and Injectable. The Canine Arthritis Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Canine Arthritis Treatment Market.

2) Identify growth segments and opportunities in the industry.

3) Facilitate decision making on the basis of strong historic and forecast of Canine Arthritis Treatment Market.

4) Assess your competitors refining portfolio and its evolution.

Canine arthritis may be a chronic condition that ends up in inflammation of 1 or a lot of joints and progresses over time if left untreated. the foremost usually affected joints embody the knee, elbow, shoulder, hip and back. There are numerous causes of inflammatory disease in dogs like traumatic injuries, obesity, failure of correct bone development and lots of others. There are many sorts of canine arthritis however the foremost common is arthritis. It affects one in five adult dogs. The prevalence of arthritis will increase with the age of canines. Its a chronic disease characterised by the loss of gristle. It conjointly includes alternative abnormalities like osteophytotic in response to inflammation and pain.

The Canine Arthritis Treatment Market has been segmented as below:

By Treatment Type:

By Route of Administration:

By End-User:

This report provides:

1) An overview of the global market for Canine Arthritis Treatment Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for Canine Arthritis Treatment Market.

4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Report Scope:

The scope of the report includes a detailed study of Canine Arthritis Treatment Market with the reasons given for variations in the growth of the industry in certain regions.

Request Sample Report from here: https://www.marketresearchengine.com/canine-arthritis-treatment-market

Table of Contents

4.1 Introduction

4.2 Drivers

4.3 Restrains

4.4 Industry Trends

4.5 Porters Five Forces Analysis

10.1 Elanco (Eli Lilly and Company)

10.2 Norbrook Laboratories Limited

10.3 Aratana Therapeutics Inc.

10.4 Dechra Pharmaceuticals Plc

10.5 VetStem Biopharma

10.6 Zoetis Inc.

10.7 Vetoquinol S.A.

10.8 Boehringer Ingelheim

10.9 Bayer AG

Other Related Market Research Reports:

Cardiac Assist Devices Market is Supposed to Reach at a CAGR of 10.02% by 2024

Cardiac Rehabilitation Devices Market is Supposed to Reach US$ 170 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Go here to read the rest:
Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-...

Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results – Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics LLC, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that results from a safety review from preclinical and two Phase 1-2 studies evaluating its drug candidate onapristone extended release (ONA-ER) for the treatment of progesterone receptor (PR) positive cancers has been published in the journal Drug Safety. ONA-ER is an investigational, potentially best-in-class oral progesterone receptor (PR) antagonist. If approved, ONA-ER would be the first FDA-approved medication for PR+ cancers.

Antiprogestins demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone was previously evaluated in Phase 2 studies for metastatic breast cancer. Due to liver enzyme elevations identified during these studies, further development was halted. Evaluation of antiprogestin pharmacology and pharmacokinetic (PK) data suggests that liver enzyme elevations might be related to off-target effects associated with serum Cmax levels. If correct, this suggests the use of pharmaceutic strategies targeting efficacious systemic dose levels, but with a diminished Cmax. One such strategy twice-daily dosing of an extended release (ER) formulation of onapristone (ONA-ER) was developed and clinically evaluated in two phase 1-2 studies in PR-positive malignancies. In light of renewed interest in antiprogestin therapy for treating PR-positive breast and gynecologic cancer, the publication authors assessed the hepatotoxic potential of: (a) onapristone in liver-focused preclinical toxicology models, and (b) ONA-ER based on data from two phase 1-2 studies involving breast, ovarian, endometrial, and prostate cancer patients.

These results suggest that the extended-release formulation by reducing drug exposure may be associated with a reduced risk of hepatotoxicity, and supports the continued clinical evaluation of ONA-ER for treating PR-positive cancers, said study author James H. Lewis, MD, Director of Hepatology at MedStar Georgetown University Hospital.

In the Phase 1-2 trials, ONA-ER at escalating doses of 10 mg to 50 mg twice-a-day had a favorable safety and tolerability profile at all doses. There were no treatment-related severe adverse events among patients treated with ONA-ER. No clinical trial subject receiving ONA-ER developed liver test elevations meeting Hys Law criteria or other clinically significant hepatic injury considered to be drug-related.

Poor tolerability has limited the potential of antiprogestins for cancer patients, said Martin Lehr, Chief Executive Officer of Context. We are pleased with the results from this review, which highlight the potential of ONA-ER to meet a significant unmet need for a well tolerated treatment for PR-positive cancers.

About Onapristone ER

Onapristone ER (extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target progesterone receptor (PR) positive cancers. Preclinical and clinical data suggest that onapristone ER has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. Onapristone ER is currently being evaluated in patients with PR+ rare ovarian and endometrial cancers in the ongoing Phase 2 ONWARD 220 clinical trial. Additional Phase 2 clinical trials in ER+, PR+, HER2- breast cancer and PR-positive endometrial cancers will be initiated in 2020. Onapristone ER is an investigational drug that has not been approved for marketing by any regulatory authority.

About Context Therapeutics

Context Therapeutics LLC is a clinical-stage biopharmaceutical company advancing medicines to treat hormone driven cancers. Contexts lead program is onapristone ER, an investigational Phase 2 drug that is being developed for progesterone receptor positive breast, ovarian and endometrial cancers. For more information on Context, visit http://www.contexttherapeutics.com.

Here is the original post:
Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results - Business Wire

Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic – 3rd Watch News

Microcarrier system offers a system matrix which would develops the growth of adherent cells in bioreactors. Microcarrier system is beneficial for a numerous of parameters such as better cell yields, large culture surface area, and also decrease the risk of contamination which will provide advantage to the growth of global microcarrier system market. A shrill trend in the application of microcarrier system is for treatment of wide conditions and cost-effective therapy which are propelling the growth of the microcarrier system market. Additionally microcarrier system market working on marketing strategies so that potential population can access to biopharmaceuticals.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/31443

The major driving factor for microcarrier system market is growing inclination towards research & development activities in cell therapy research as well as the favorable funding is anticipated to drive growth within the stem cell therapy sector. The emerging demand for microcarrier system market is largely arising from the increasing incidences of cancer. Growing demand for stem cell therapy coupled with growing adoption for cell-based vaccines will foster the microcarrier system market growth. The endlessly increasing cost-effective cell production for numerous stem cell therapies in large scale is fueling the demand for microcarrier system market. Moreover, the growing demand for detection of numerous other diseases for instance cancer and other hereditary diseases increases the probabilities for stem therapy techniques consequently increasing demand for microcarrier system market. As well as manufacturers are focusing on developing innovative techniques for stem cell therapy which will boost the growth of the microcarrier system market. However, limitations in the production of high-density cell culture can restrain the growth of microcarrier system market.

The global microcarrier system market is segmented on the basis of Product Type, Application, End User and Geography:

The global microcarrier system market is into initial stages attributed to focus on acclimatizing to the new technique in stem cell therapy and its innovation. Consequently, the microcarrier system is projected to demonstrate exponential growth potential for the treatment of cancer patient owing to a higher inclination towards cost-effective therapy cost. The major parameter in the microcarrier system market is concentrating on increased manufacturing efficacy with effective therapies to the patient. The increasing new applications in hereditary diseases are anticipated to offer growth opportunities for the microcarrier system market. However recent development in the growth of adherent cells can boost microcarrier system market, for instance in 2018, the newly designed system for the development of adherent cells on microcarriers and rapid process development of vaccines was launched by Sartorius Stedim Biotech (SSB) which is mini bioreactor vessel for ambr 250.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/31443

Geographically, the global microcarrier system market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as a prominent market in the global microcarrier system market due to favorable reimbursement scenarios and superior healthcare infrastructure. Increase in research funds which are provided by various biopharmaceutical companies will fuel the growth of global microcarrier system market in European countries like France, the UK, Spain, Germany, and others. The microcarrier system market in south Asia and East Asia is expected to grow substantially due to the high number of patient population and growing demand for cell-based vaccines. The Middle East and Africa (MEA) can make symbolic progress due to increasing investment in the Middle Eastern countries like Israel, Dubai, and others.

Some of the major key players competing in the global microcarrier system Market are General Electric Company, Thermo Fisher Scientific Inc., Lonza Group, Eppendorf, HiMedia Laboratories, Merck KGaA, Danaher Corporation, Becton, Dickinson and Company and Corning Incorporated, The Sartorius group and among others.

Continue reading here:
Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic - 3rd Watch News

R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico – Yahoo Finance

R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

SAN DIEGO, June 29, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

Millions of individuals suffer from chronic liver disease, which occurs due to a number of causes such as hepatitis, cirrhosis, metabolic diseases, and other conditions. All too often, conventional therapies fail to provide the desired result.

Stem cell therapy has been shown in several studies to produce beneficial results for liver failure. This includes a study of 43 patients from 2012 in Stem Cells and Translational Medicine noting significant increase in survival rates, along with no adverse events.

In its new program, R3 International uses the same weight based protocol. Each treatment provides up to 50 million stem cells at a time, with the treatment occurring at the stem cell therapy clinic in Tijuana Mexico. To date, hundreds of patients have received stem cell therapy in Mexico with R3 for a variety of conditions. No adverse events have been reported, and outcomes have been sensational for organ failure, arthritis, diabetes, dementia, stroke, stem cells for Lyme disease, Crohns and many more.

In order to receive treatment, patients start with a free phone consultation with the licensed, experienced stem cell doctor from R3 International. After the consult and review of medical records, the doctor provides a treatment recommendation. Then the dedicated patient concierge representative will assist with travel logistics and transportation from San Diego to the clinic is provided.

Simply call (888) 988-0515 to schedule the phone consultation and learn about options for treatment.

SOURCE R3 Stem Cell International

Original post:
R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico - Yahoo Finance

Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations – AJMC.com Managed Markets Network

The decision comes almost exactly a month after results from KEYNOTE-177 were presented at the annual meeting of the American Society of Clinical Oncology.

Merck, which makes pembrolizumab, sold as Keytruda, announced the approval in a statement.

The approval covers patients who have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and is based on results of KEYNOTE-177, a phase 3 trial of 307 patients that found the programmed cell death-1 (PD-1) inhibitor trimmed the risk of death of disease progression 40% compared with chemotherapy, which is the current standard of care (HR = 0.60, 95% CI: 0.45-0.80, P = .0004).

Results presented at ASCO showed that pembrolizumab doubled progression-free survival in these colorectal cancer patients, from 8.2 months to 16.5 months. Lead study author Thierry Andr MD, of the Sorbonne Universit and Hpital Saint Antoine in Paris, said at the time that the findings would change the standard of care. No medical treatment has shown such an improvement, Andr said.

Discussant Michael Overman, MD, of The University of Texas MD Anderson Cancer Center, agreed and said the tumors treated in the study were particularly good candidates for immunotherapy. From now on, he said, It is critical that we test all colorectal cancer patients for mismatch repair or microsatellite status.

The approval came less than a month after Merck submitted a supplemental Biologics License Application, which was handled through FDAs Real-Time Oncology Review pilot program. According to the Merck statement, the approval was reviewed under Project Orbis, an initiative of the FDA Oncology Center of Excellence that allows for concurrent submission and review of oncology drugs among its international partnersin this case, regulators in Australia, Canada, and Switzerland.

Todays approval has the potential to change the treatment paradigm for the first-line treatment of patients with MSI-H colorectal cancer, based on the important findings from KEYNOTE-177 that showed Keytruda monotherapy demonstrated superior progression-free survival compared to standard of care chemotherapy, Roy Baynes, MD, PhD, senior vice president and head of global clinical development, chief medical officer for Merck Research Laboratories, said in the statement.

At ASCO, Andr trumpeted the value of biomarker-driven research, and Baynes did the same today. Our commitment to pursuing biomarker research continues to help us bring new treatments to patients, he said, particularly for those who have few available options.

Immune-related adverse events can include pneumonitis, colitis, hepatitis, skin reactions, renal dysfunction, and endocrinological abnormalities. Patients taking the PD-1 inhibitor may experience solid organ transplant rejection or complications from stem cell transplant.

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center. said in the statement that patients with colorectal cancer and the genetic mutations in the study have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options.

About 5% of metastatic colorectal cancer patients have MSI-H/dMMR. Pembrolizumabs effectiveness when this mutation is present is well-recognized, and led to FDAs firsttissue-agnostic approvalin May 2017.

See original here:
Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations - AJMC.com Managed Markets Network

Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic – Jewish Life News

2014-2029 Report on Global Stem Cell Therapy Market By Player, Region, Type, Application And Sales Channel the new research report adds in kandjmarketresearch.com research reports database. Complete report On Stem Cell Therapy Research Report Spread Across 109 Pages, With Summarizing Top Companies and Stem Cell Therapy with Tables and Figures.

Market Overview

The global Stem Cell Therapy market has been studied by a set of researchers for a defined forecast period of 2014 to 2029. This study has provided insights to the stakeholders in the market landscape. It includes an in-depth analysis of various aspects of the market. These aspects include an overview section, with market segmentation, regional analysis, and competitive outlook of the global Stem Cell Therapy market for the forecast period. All these sections of the report have been analyzed in detail to arrive at accurate and credible conclusion of the future trajectory. This also includes an overview section that mentions the definition, classification, and primary applications of the product/service to provide larger context to the audience to this report.

Market Dynamics

The report on the global Stem Cell Therapy market includes a section that discusses various market dynamics that provide higher insight in the relationship and the impact of change these dynamics hold on the market functioning. These dynamics include the factors that are providing impetus to the market over the forthcoming years for growth and expansion. Alternatively, it also includes factors that are poised to challenge the market growth over the forecast period. These factors are expected to reveal certain hidden trends that aid in the better understanding of the market over the forecast period.

The Final Report Will Include the Impact of COVID 19 Analysis in This Stem Cell Therapy Industry.

Get Free Sample Report on Stem Cell Therapy @: https://www.kandjmarketresearch.com/sample-request/328640

Key Players

The global Stem Cell Therapy market report has provided a profiling of significant players that are impacting the trajectory of the market with their strategies for expansion and retaining of market share.

Leading players of Stem Cell Therapy including:

Market split by Type, can be divided into:

Market split by Application, can be divided into:

Do You Have Any Query or Specific Requirement? Ask to Our Trade Expert @ https://www.kandjmarketresearch.com/enquiry/328640

Market Segmentation

The global Stem Cell Therapy market has been studied for a detailed segmentation that is based on different aspects to provide insight in the functioning of the segmental market. This segmentation has enabled the researchers to study the relationship and impact of the growth chart witnessed by these singular segments on the comprehensive market growth rate. It has also enabled various stakeholders in the global Stem Cell Therapy market to gain insights and make accurate relevant decisions. A regional analysis of the market has been conducted that is studied for the segments of North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

Research Methodology

The global Stem Cell Therapy market has been analyzed using Porters Five Force Model to gain precise insight in the true potential of the market growth. Further, a SWOT analysis of the market has aided in the revealing of different opportunities for expansion that are inculcated in the market environment.

Market split by Sales Channel, can be divided into:

Market segment by Region/Country including:

Read More Detailed Information regarding Stem Cell Therapy Industry with Covid-19 Updates @: https://www.kandjmarketresearch.com/reports/328640-2014-2029-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:

KandJ Market Research

(Part of KnowledgeNJournals Research)

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

Call us: +1 661 636 6162 | +91 932 580 2062

Go here to read the rest:
Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic - Jewish Life News

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in…

June 30, 2020 07:00 ET | Source: Genespire

Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells

Italy, Milan, 30 June 2020: The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire, a gene therapy company developing transformative therapies for genetic diseases, announce today the publication of data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology.

The paper, entitled Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, outlines technology developed by Pr. Luigi Naldini and his team at SR-Tiget, which is included in the strategic alliance with Genespire. It shows increased homology directed recombination (HDR) efficiency in HSCs by forcing cell-cycle progression and transiently upregulating components of the HDR machinery. The findings are validated by clonal tracking of the edited HSCs in experimental transplantation models, which shows improved polyclonal engraftment by long-term repopulating HSCs.

People with genetic diseases affecting the hematopoietic lineage may benefit from corrective targeted gene therapy in HSCs. These cells are self renewing and can differentiate into all the cell types of the hematopoietic lineage, therefore providing the potential for a one-time therapy. As compared to standard gene replacement approaches, gene editing corrects the disease-causing mutation in situ, restoring both function and physiological expression control of the affected gene. In principle, this targeted strategy may fulfill the goal of precision medicine at the most stringent genetic level. Its realization in HSCs, however, has been hampered until now by low efficiency of HDR-driven repair, likely because of the quiescent state of the more primitive progenitors. Use of the improved gene editing technology developed by SR-Tiget has been shown to yield a greater percentage of gene-edited HSCs and increased clonality, or the number of modified cells transplanted and engrafted in the recipient. In a clinical setting this should lead to increased hematopoietic cells chimerism in the patient receiving the corrective HSC therapy, and could accelerate the hematopoietic recovery after conditioning and increase the size, long-term stability, and safety of the engineered cell graft.

This approach can be applied to genetic diseases originating in the hematopoietic lineage, including primary immune deficiencies (PIDs), a key area of focus for Genespire. Genespire will continue to work with SR-Tiget and apply this technology to its future pipeline of gene therapies.

Julia Berretta, Chief Executive Officer of Genespire, commented: The focus of Genespires alliance with SR-Tiget is to research and develop novel gene therapies, addressing severe diseases with high unmet medical need. We are pleased with the publication of these data in Nature Biotechnology, which provide valuable insights into this pioneering technology developed by SR-Tiget, and we look forward to our future work with them to translate cutting edge science into transformational therapies.

Professor Luigi Naldini, Director of SR-Tiget and scientific co-founder of Genespire, said Our findings elucidate and overcome two main biological barriers to efficient HDR-mediated gene editing in HSCs, and show by clonal tracking that our enhanced editing protocol preserves their multilineage and self-renewal capacity long term after serial transplant. We look forward to our future work with Genespire to explore its potential in primary immunodeficiencies.

The full publication details are below and can be accesed online here.

Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking Samuele Ferrari, Aurelien Jacob, Stefano Beretta, Giulia Unali, Luisa Albano, Valentina Vavassori, Davide Cittaro, Dejan Lazarevic, Chiara Brombin, Federica Cugnata, Anna Kajaste-Rudnitski, Ivan Merelli, Pietro Genovese and Luigi Naldini

Enquiries:

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About SR-Tiget

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Go here to read the rest:
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in...

Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data – GlobeNewswire

June 29, 2020 17:00 ET | Source: Reports and Data

New York, June 29, 2020 (GLOBE NEWSWIRE) -- The globalresearch antibodies marketis expected to reach USD 5.33 Billion by 2027, according to a new report by Reports and Data. Rising research activities in the field of stem cells is a significant factor driving the growth of the market. Stem cells have the capability of discerning and regenerating various kinds of cells in the human body. These cells possess the potential to cure life-threatening diseases such as oncological and blood-related disorders. Cord blood stem cells find application in the treatment of more than 80 blood-related ailments, such as Sickle Cell Disease. It is projected that over 27 million babies across the globe are born with some kind of blood disorder. As per the World Health Organization, in 2008, 100,000 children were found to be suffering from thalassemia in India.

Increased funding for research and development activities is instrumental in driving the growth of the market. Investment in the healthcare R&D by the US has witnessed a growth of 18.1% between the years 2014 and 2017. In the year 2017, in the US, the overall expenditure on healthcare R&D was USD 182.30 billion. Besides, according to the 2016 financial statements of Celgene Corporation, a leading biopharmaceutical firm, the R&D expenditure grew by USD 772.8 million (21.0% more than 2015 expenses) in 2016 to USD 4.47 billion. Also, a USD 892.9 million of R&D asset acquisition spending, comprising a USD 625.0 million purchase of Engmab AG, a private firm engaged in T-cell bispecific antibodies, added to the overall R&D expenses of the Celgene.

However, cost-prohibitive research antibodies and issues related to the quality of nontherapeutic antibodies may create hindrances in the growth of the market in the upcoming years.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3270

COVID-19 Impact As the global economies are experiencing the negative impact of the Covid-19 pandemic, organizations are suffering losses, among various other challenges. Nevertheless, firms in the pharmaceutical industry are of immense importance in combatting the pandemic and are witnessing positive growth in the contagious disease landscape with the race for treatment approval therapy gaining momentum.

In April 2020, the ICMR (Indian Council of Medical Research) announced that it would fast-track funding proposals intended for immunology approaches for the treatment of coronavirus, a step to bridge the research gap in the country to combat the pandemic.

Further key findings from the report suggest

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3270

For the purpose of this report, Reports and Data have segmented the global research antibodies market on the basis of product, antibody type, technology, application, end-users, and region:

ProductOutlook (Revenue, USD Million; 2017-2027)

Antibody TypeOutlook (Revenue, USD Million; 2017-2027)

TechnologyOutlook (Revenue, USD Million; 2017-2027)

ApplicationOutlook (Revenue, USD Million; 2017-2027)

Industry VerticalOutlook (Revenue, USD Million; 2017-2027)

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/research-antibodies-market

Regional Outlook (Revenue, USD Million; 2017-2027)

Take a Look at our Related Reports:

E-Prescribing Market: https://www.reportsanddata.com/report-detail/e-prescribing-market

Mobile Health (mHealth) Market: https://www.reportsanddata.com/report-detail/mobile-health-mhealth-market

Artificial Intelligence in Drug Discovery Market: https://www.reportsanddata.com/report-detail/artificial-intelligence-in-drug-discovery-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Visit link:
Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data - GlobeNewswire